IP Library › Granted Patent US 12,331,293
Granted Patent B2
US 12,331,293 · App. 17/309,140 · Granted Jun 17, 2025

Bispecific antisense oligonucleotides for dystrophin exon skipping

Inventors: Judith Christina Theodora van Deutekom (Dordrecht, NL); Nicole Anne Datson (Oegstgeest, NL)
Assignee: BIOMARIN TECHNOLOGIES B.V.
C12N15/113A61P21/00C12N2310/11C12N2310/315C12N2310/321C12N2310/3231C12N2310/51C12N2320/33
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,331,293
App. No.
17/309,140
Granted
Jun 17, 2025
Kind
B2
Abstract

The current invention provides splice-switching compounds with improved characteristics that enhance clinical applicability preferably for treating, ameliorating, preventing, and/or delaying neuromuscular disorders, more specifically DMD.

Claims (27)

1. A compound comprising a first and a second antisense oligonucleotide (AON) linked to each other by a linking moiety, wherein said first antisense oligonucleotide (AON) consists of the base sequence of SEQ ID NO: 14, and wherein said second antisense oligonucleotide (AON) consists of the base sequence of SEQ ID NO: 198, wherein sequences complementary to SEQ ID NO: 14 and 198 are located within exon 51 of dystrophin pre-mRNA.

2. A compound according to claim 1 , wherein said linking moiety links the 3′ terminal monomer of said first AON with the 5′ terminal monomer of said second AON or links the 5′ terminal monomer of said first AON with the 3′ terminal monomer of said second AON.

3. A compound according to claim 1 , wherein said linking moiety is a polyethylene glycol (PEG) linker, a triethylene glycol (TEG) or hexaethylene glycol (HEG) linker.

4. A compound according to claim 3 , wherein said linking moiety is a triethylene glycol (TEG) or hexaethylene glycol (HEG) linker.

5. A compound according to claim 1 , wherein said first and/or second antisense oligonucleotide comprises:

i) at least one 2′-substituted monomer and optionally a phosphorothioate backbone linkage, and/or

ii) a 5-methylcytosine and/or a 5-methyluracil base, and/or

iii) at least one monomer comprising a bicyclic nucleic acid (BNA) scaffold modification.

6. A compound according to claim 5 , wherein said first and/or second antisense oligonucleotide comprises only 2′-substituted monomers linked by phosphorothioate backbone linkages.

7. A compound according to claim 5 , wherein all cytosine bases are 5-methylcytosine bases and/or wherein all uracil bases are 5-methyluracil bases of said first and/or second antisense oligonucleotide.

8. A compound according to claim 5 , wherein said first and/or second antisense oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8 or 9 monomers that comprise a bicyclic nucleic acid (BNA) scaffold modification, a bridged nucleic acid scaffold modification, or a locked nucleic acid (LNA) scaffold modification.

9. A compound according to claim 8 , wherein said first and/or second antisense oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8 or 9 monomers that comprise a bridged nucleic acid scaffold modification.

10. A compound according to claim 8 , wherein said first and/or second antisense oligonucleotide comprises 1, 2, 3, 4, 5, 6, 7, 8 or 9 monomers that comprise a locked nucleic acid (LNA) scaffold modification.

11. A compound according to claim 8 , wherein said first and/or second oligonucleotide comprises BNA modifications as selected from the set consisting of:

(i) a single BNA scaffold modification in the monomer at the 5′-terminus,

(ii) a single BNA scaffold modification in the monomer at the 3′-terminus,

(iii) two BNA scaffold modifications where one is in the monomer at the 5′-terminus and the other is in the monomer at the 3′-terminus,

(iv) two BNA scaffold modifications, one in each of the two monomers that are closest to the 5′-terminus,

(v) two BNA scaffold modifications, one in each of the two monomers that are closest to the 3′-terminus, and

(vi) four BNA scaffold modifications, one in each of the two monomers that are closest to the 5′-terminus and one in each of the two monomers that are closest to the 3′-terminus;

wherein, optionally 1, 2, 3, 4 or 5 additional BNA scaffold modifications are present.

12. A compound according to claim 11 , wherein said first antisense oligonucleotide is represented by a nucleotide sequence consisting of any one of:

SEQ ID NO: 15911 to 15922, or 15977 to 15988 (derived from SEQ ID NO: 14), and wherein said second antisense oligonucleotide is represented by a nucleotide sequence consisting of any one of:

SEQ ID NO: 15948 to 15962, or 16014 to 16028 (derived from SEQ ID NO: 198).

13. A composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

14. A method for treating Duchenne Muscular Dystrophy (DMD), comprising administering to a subject a compound according to claim 1 .

15. A method for skipping of exon 51 of the dystrophin pre-mRNA, comprising administering to a subject a compound according to claim 1 .

Assignments (3)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2021
From: VAN DEUTEKOM, JUDITH CHRISTINA THEODORA; DATSON, NICOLE ANN
To: BIOMARIN TECHNOLOGIES B.V.
Reel/Frame 056689/0782 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2021
From: VAN DEUTEKOM, JUDITH CHRISTINA THEODORA; DATSPM, NICOLE ANN
To: BIOMARIN TECHNOLOGIES B.V.
Reel/Frame 056504/0368 →
Priority Claims (1)
EP 18204170 · Nov 2, 2018 · regional
Continuity (1)
Related Publication 20220025368A1 · Jan 27, 2022
References Cited (147)
US 7534879B2 · van Deutekom · 2009 [cited by applicant]
US 7973015B2 · van Ommen et al. · 2011 [cited by applicant]
US 8263760B2 · de Kimpe et al. · 2012 [cited by applicant]
US 8268962B2 · Heemskerk et al. · 2012 [cited by applicant]
US 8304398B2 · 't Hoen et al. · 2012 [cited by applicant]
US 8361979B2 · Aartsma-Rus et al. · 2013 [cited by applicant]
US 8519097B2 · Heemskerk et al. · 2013 [cited by applicant]
US 8609065B2 · Kuik-Romeijn et al. · 2013 [cited by applicant]
US 8759507B2 · van Deutekom · 2014 [cited by applicant]
US 8802645B2 · van Ommen et al. · 2014 [cited by applicant]
US 9139828B2 · Platenburg et al. · 2015 [cited by applicant]
US 9243245B2 · de Kimpe et al. · 2016 [cited by applicant]
US 9499818B2 · van Deutekom · 2016 [cited by applicant]
US 9528109B2 · de Kimpe et al. · 2016 [cited by applicant]
US 9840706B2 · Watanabe et al. · 2017 [cited by applicant]
US 9896687B2 · van Ommen et al. · 2018 [cited by applicant]
US 9926557B2 · de Kimpe et al. · 2018 [cited by applicant]
US 10100304B2 · van Deutekom · 2018 [cited by applicant]
US 10113165B2 · Van Deutekom et al. · 2018 [cited by applicant]
US 10179912B2 · de Visser et al. · 2019 [cited by applicant]
US 10190116B2 · van Deutekom · 2019 [cited by applicant]
US 10246707B2 · Platenburg et al. · 2019 [cited by applicant]
US 10533171B2 · Van Deutekom et al. · 2020 [cited by applicant]
US 10544416B2 · Van Deutekom · 2020 [cited by applicant]
US 10876114B2 · Van Deutekom · 2020 [cited by applicant]
US 10913946B2 · De Visser et al. · 2021 [cited by applicant]
US RE48468E · De Kimpe et al. · 2021 [cited by applicant]
US 11034956B2 · Van Deutekom et al. · 2021 [cited by applicant]
US 11053497B2 · Wakayama et al. · 2021 [cited by applicant]
US 20080200409A1 · Wilson et al. · 2008 [cited by applicant]
US 20090269755A1 · Aartsma-Rus et al. · 2009 [cited by applicant]
US 20110184050A1 · De Kimpe et al. · 2011 [cited by applicant]
US 20130059902A1 · Corey et al. · 2013 [cited by applicant]
US 20140045763A1 · Aguilera Diez et al. · 2014 [cited by applicant]
US 20150191725A1 · van Deutekom · 2015 [cited by applicant]
US 20150337002A1 · Obika et al. · 2015 [cited by applicant]
US 20150368287A1 · Mitsuoka et al. · 2015 [cited by applicant]
US 20160010090A1 · Vagle · 2016 [cited by applicant]
US 20170067048A1 · Wakayama · 2017 [cited by examiner]
US 20170145409A1 · Seth et al. · 2017 [cited by applicant]
US 20170204410A1 · Watanabe · 2017 [cited by examiner]
US 20180028554A1 · Van Deutekom et al. · 2018 [cited by applicant]
US 20190127733A1 · Butler et al. · 2019 [cited by applicant]
US 20190177723A1 · Dickson · 2019 [cited by applicant]
US 20200239886A1 · De Kimpe et al. · 2020 [cited by applicant]
US 20200291399A1 · Van Deutekom et al. · 2020 [cited by applicant]
US 20200385717A1 · Van Deutekom · 2020 [cited by applicant]
US 20210108204A1 · de Visser et al. · 2021 [cited by applicant]
US 20210139904A1 · Van Deutekom · 2021 [cited by applicant]
EP 3118311A1 · 2017 [cited by applicant]
EP 3159409A1 · 2017 [cited by applicant]
WO WO2004045543A2 · 2004 [cited by examiner]
WO 2010048586A1 · 2010 [cited by applicant]
WO 2016017422A1 · 2016 [cited by applicant]
WO 2018007475A1 · 2018 [cited by applicant]
WO WO2018014042A1 · 2018 [cited by examiner]
O'Dea T and McLaughlin LW, Curr Protoc Nucleic Acid Chem. May 2001; Chapter 5: Unit 5.3. (Year: 2001). [cited by examiner]
Gapmer Design [retrieved on Jun. 12, 2024], retrieved from the Internet: <URL: https://www.biosyn.com/tew/Gapmer-Design.aspx#!>) (Year: 2016). [cited by examiner]
Wilton et al., Molecular Therapy 2007; 15:1288-1296. [cited by applicant]
Bestas et al., Nucleic Acid Ther. 2014; 24:13-24. [cited by applicant]
Aartsma-Rus et al., Hum. Mol. Gen. 2003; 12(8):907-14. [cited by applicant]
Arai et al., Bioorg. Med. Chem. 2011; 21:6285. [cited by applicant]
Beekman et al., PLoS One 2014; 9(9):el07494. [cited by applicant]
Beekman et al., PLoS One 2018; 13(4):e0195850. [cited by applicant]
Bolli et al., Chem Biol. 1996; 3(3):197-206. [cited by applicant]
Braida et al., Human Molecular Genetics 2010; 9:1399-1412. [cited by applicant]
Bruno, Advanced Drug Delivery Reviews 2011; 63:1210-1226. [cited by applicant]
Cao et al., Mol. Ther. Nucleic Acids 2016; 5(6):e329. [cited by applicant]
Cartegni et al., Nat. Rev. Genet. 2002; 3(4):285-98. [cited by applicant]
Cartegni et al., Nucleic Acids Res. 2003; 31(13):3568-71. [cited by applicant]
Cirak et al., Lancet 2011; 378:595-605. [cited by applicant]
Diebold et al., Eur. J. Immunol. 2006; 36(12):3256-67. [cited by applicant]
Disterer et al., Mol. Ther. 2013; 21(3):602-609. [cited by applicant]
Abdur Rahman et al., J. Am. Chem. Soc. 2008; 130(14):4886-4896. [cited by applicant]
Morita et al., Nucl. Acids Symp. Series 2001; 1(1):241-242. [cited by applicant]
Zhou et al., J. Org. Chem. 2010; 75(7):2341-2349. [cited by applicant]
Dugovic et al., J. Org. Chem. 2014; 79(3):1271-1279. [cited by applicant]
Medvecky et al., J. Org. Chem. 2015; 80(7):3556-3565. [cited by applicant]
Dominski and Kole, PNAS 1993; 90(18):8673-8677. [cited by applicant]
Dom and Kippenberger, Curr. Opin. Mol. Ther. 2008; 10(1 ):10-20. [cited by applicant]
Du et al., PNAS 2007; 104(14):6007-12. [cited by applicant]
Ehmsen J et al., J. Cell Sci. 2002; 115(Pt14):2801-2803. [cited by applicant]
Evers et al., PLoS One 2011; 6(9):e24308. [cited by applicant]
Evers et al., Nucleic Acid Ther. 2014; 24(1):4-12. [cited by applicant]
Fairbrother et al., Science 2002; 297(5583):1007-1013. [cited by applicant]
Fairbrother et al., Nucleic Acids 2004; 32:W187-190. [cited by applicant]
Friedman et al., J. Biol. Chem. 1999; 274(51):36193-36199. [cited by applicant]
Gao et al., Cell Transplant 2008; 17(7):723-34. [cited by applicant]
Gao et al., Mol. Ther. Nucleic Acids 2015; 4:e255. [cited by applicant]
Gedicke-Homung et al., EMBO Mol. Med. 2013; 5(7):1060-77. [cited by applicant]
Giles et al., Antisense Nucleic Acid Drug Dev. 1999; 9(2):213-20. [cited by applicant]
Goemans et al., N. Engl. J. Med. 2011; 364(16):1513-22. [cited by applicant]
Goto et al., J. Invest. Dermatol. 2006; 126(12):2614-20. [cited by applicant]
Goyenvalle et al., Nat. Med. 2015; 21(3):270-5. [cited by applicant]
Han et al., Nature Communications 2016; 7:10981. [cited by applicant]
Hanessian et al., J. Org. Chem. 2013; 78(18):9064-9075. [cited by applicant]
Heemskerk et al., Mol. Ther. 2010; 18(6):1210-7. [cited by applicant]
Hodgetts et al., Neuromuscular Disorders 2006; 16:591-602. [cited by applicant]
Hua et al., Am. J. Hum. Genet. 2008, 82(4): 834-48. [cited by applicant]
Hua et al., Nature 2011; 478(7367):123-6. [cited by applicant]
Karras et al., Biochemistry 2001; 40(26):7853-9. [cited by applicant]
Khoo et al., BMC Mol. Biol. 2007; 8:3. [cited by applicant]
Krieg et al., Nature 1995; 374:546-549. [cited by applicant]
Krieg, Curr. Opin. Immunol. 2000; 12: 35-43. [cited by applicant]
Kumar, Pharm. Technol. 2008; 3:128. [cited by applicant]
Lentz et al., Nat. Med. 2013; 19(3):345-350. [cited by applicant]
Mercatante et al., J. Biol. Chem. 2002; 277(51):49374-82. [cited by applicant]
Monaco et al., Genomics 1988; 2:90-95. [cited by applicant]
Murray et al., Nucl. Acids Res. 2012; 40(13):6135-6143. [cited by applicant]
Nishida et al., Chem. Commun. 2010; 46:5283. [cited by applicant]
Opalinska et al., Nucleic Acids Res. 2004; 32(19):5791-5795. [cited by applicant]
Osawa et al., J. Org. Chem. 2015; 80(21):10474-10481. [cited by applicant]
Osorio et al., Sci. Transl. Med. 2011; 3(106):106ra107. [cited by applicant]
Owen et al., PLOS One 2012; 7(3):e33576. [cited by applicant]
Peacey et al., NAR 2012; 40(19):9836-49. [cited by applicant]
Peacock et al., J. Am. Chem. Soc. 2011; 133:9200. [cited by applicant]
Popovic et al., J. of Immunol. 2006; 177:8701-8707. [cited by applicant]
Renshaw et al., Mol. Cancer Ther. 2004; 3(11):1467-84. [cited by applicant]
Rincon et al., Am. J. Hum. Genet. 2007; 81(6):1262-1270. [cited by applicant]
Seth et al., J. Org. Chem. 2010; 75:1569-1581. [cited by applicant]
Spitali et al., FASEB J. 2013; 27(12):4909-4916. [cited by applicant]
Taniguchi-Ikeda et al., Nature 2011; 478(7367):127-31. [cited by applicant]
Tyson-Capper et al., Mol. Pharmacol. 2006; 69(3):796-804. [cited by applicant]
Uchikawa et al., J. Hum. Genet. 2007; 52(11):891-897. [cited by applicant]
Uehara et al., FASEB J. 2013; 27(1):76-85. [cited by applicant]
Van Deutekom et al., N. Engl. J. Med. 2007; 357(26):2677-86. [cited by applicant]
Van Ommen et al., Curr. Opin. Mol. Ther. 2008; 10(2): 140-9. [cited by applicant]
Veltrop et al., PLoS One 2018; 13(2):e0193289. [cited by applicant]
Verheul et al., PLoS One 2016; 11(9):e0162467. [cited by applicant]
Vetrini et al., Hum. Mutat. 2006; 27(5):420-6. [cited by applicant]
Vickers et al., J. Immunol. 2006; 176(6):3652-61. [cited by applicant]
Voit et al., Lancet Neurol. 2014; 13(10):987-96. [cited by applicant]
Wagner, H., Adv. Immunol. 1999; 73:329-368. [cited by applicant]
Wein et al., Hum. Mut. 2010; 31(2):136-42. [cited by applicant]
Wheeler et al., J. Clin. Invest. 2007; 117(12):3952-7. [cited by applicant]
Williams et al., Oligonucleotides 2006; 16(2):186-95. [cited by applicant]
Yamamoto et al., Org. Biomol. Chem. 2015; 13:3757. [cited by applicant]
Yokota et al., Acta Myol. 2007; 26(3):179-84. [cited by applicant]
Straarup et al., Nucleic Acids Res. 2010; 38(20):7100-7111. [cited by applicant]
Zammarchi et al., PNAS 2011; 108(43):17779-84. [cited by applicant]
Zuker et al., Nucleic Acids Res. 2003; 31(13):3406-15. [cited by applicant]
Guterstam, et al., BioChem. J. 2008; 412:307-313. [cited by applicant]
Biscans, et al., Bioorg. & Med. Chem. 2015; 23:5360-5368. [cited by applicant]
Dohmen, et al., Mol. Ther. Nucl. Acids 2012; 1:e7. [cited by applicant]
Gao, et al., Mol. Therapy 2014; 22(7):1333-1341. [cited by applicant]
Jirka, et al., Nucl. Acid Ther. 2014; 24(1):25-36. [cited by applicant]
Echigoya, et al., “Quantitative antisense screening and optimization for exon 51 skipping in Duchenne muscular dystrophy” Mol. Therapy, 2017, 25(11), 2561-2572. [cited by applicant]